semaglutide for alcohol use disorder shows promise as a potential medication Significant Decrease in Alcohol Use

The company will continue to cover these drugs for diabetes treatment and may offer large employers the option to keep weight-loss coverage

Side effects are significant for some people

It has shown significant promise as an effective intervention against type 2 diabetes (T2D) and excessive body weight, resulting in the United States Food and Drug Administration (FDA) approving its use against both conditions in May 2022 for T2D and November 2023 for obesity

Matria (Rio de Janeiro) 23:e12217

Every patient is different and there are no guarantees, but many studies have been conducted to estimate the weight loss that can be achieved with GLP-1 inhibitors